CRL Charles River Laboratories International Inc.

Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville

Charles River Laboratories International, Inc. (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL®) facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub. The facility is strategically co-located with Nest.Bio, a provider of rentable BSL-2 laboratory and office space. The Chestnut Street location will address an increased demand for more flexible vivarium and bench space, as well as on-demand in vivo study support services within the heart of Massachusetts’ industry-leading biopharmaceutical sector.

“We are excited to bring CRADL to Somerville’s Brickbottom District, an emerging life science hub for biotech development in which startups unable to find lab space in the increasingly crowded Cambridge environment can thrive,” said Colin Dunn, Ph.D., Corporate Senior Vice President, Global Research Models & Services, Charles River. “CRADL’s scalable contract vivarium space, combined with Charles River’s extensive preclinical network, supports clients in starting projects quickly, without the costly burden of building infrastructure.”

CRADL® is the leading space for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery and non-clinical development resources.

The new Somerville facility is strategically situated less than a mile from the established industry presence in Kendall Square. The building offers a unique coexistence of private lab suites, rentable lab benches, and office space on the same floor to enable seamless communication, collaboration, and productivity. This distinctive setup can be particularly advantageous for startup organizations, providing an efficient and streamlined environment for both research and administrative functions.

Expanding Access and Expertise to Global Ecosystems through CRADL

With the addition of a fourth Massachusetts site, the CRADL Vivarium Network operates nearly 30 facilities in key biohubs, including: San Francisco, San Diego, Seattle, Philadelphia, Chicago, Thousand Oaks, Shanghai, Chengdu and London. This network supports the growth of the entire biotech ecosystem in each city, allowing researchers to rapidly engage in their research while maintaining the flexibility to relocate or co-locate, knowing they will have reliable, high-quality facilities nearby.

Charles River is hosting a grand opening for CRADL Somerville on July 31, 2024, including guided tours and equipment demonstrations with expert staff. To learn more and register, visit: .

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

EN
06/06/2024

Underlying

Reports on Charles River Laboratories International Inc.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 March 2025 in which we reassessed the appropriateness of the rati...

 PRESS RELEASE

Charles River Laboratories to Present at Barclays Global Healthcare Co...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...

 PRESS RELEASE

Charles River Announces Agreement with Singapore General Hospital

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. “We are thrilled to leverage our cell line characterization services and comprehensive NGS testing app...

Charles River Laboratories International Inc: 3 directors

Three Directors at Charles River Laboratories International Inc bought/sold/sold after exercising options 11,989 shares at between 162.500USD and 165.010USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart whi...

 PRESS RELEASE

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.1%, and an acquisition contributed 0.9% to consolidated fourth-quarter revenue. A divestiture reduced reported revenue by 0.1%. Excluding the effect of these items, revenue declined 1.8% on an organic basis. On a seg...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch